{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:54:04Z","timestamp":1775620444037,"version":"3.50.1"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The application of human epididymis protein 4 (HE4) in diverse health diseases, especially in cancers, has been extensively studied in recent decades. To summarize the existing evidence of the aforementioned topic, we conducted an umbrella review to systematically evaluate the reliability and strength of evidence regarding the role of HE4 in the diagnostic and prognostic estimate of diverse diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Electronic searches in PubMed, Web of Science, and Embase databases were conducted from inception to September 16, 2021, for meta-analyses, which focus on the role of HE4 in the diagnosis and prognosis of diseases. This study protocol has been registered at PROSPERO (CRD42021284737). We collected the meta-analysis effect size of sensitivity, specificity, positive predictive value, and negative predictive value from diagnostic studies and gathered the hazard ratio (<jats:italic>HR<\/jats:italic>) of disease-free survival, overall survival, and progression-free survival from prognostic studies. For each systematic review and meta-analysis, we used a measurable tool for evaluating systematic reviews and meta-analysis (AMSTAR) to evaluate the methodological quality. Additionally, we assessed the quality of evidence on estimating the ability of HE4 in the diagnosis and prognosis of diverse diseases by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guideline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 20 meta-analyses including a total of 331 primary studies of different diseases were examined, mainly including ovarian cancer (OC) (<jats:italic>n<\/jats:italic> = 9), endometrial cancer (EC) (<jats:italic>n<\/jats:italic> = 6), and lung cancer (LC) (<jats:italic>n<\/jats:italic> = 4). The methodological qualities of all studies were rated as moderate (45%) or high (55%) by the AMSTAR. According to the GRADE, the certainties of 18 diagnostic pieces of evidence (9 for sensitivity and 9 for specificity) were rated as moderate (34%), low (33%), and very low (33%). Moreover, outcomes from prognosis studies showed evidence (1 for disease-free survival) with high certainty in regard to cancers (such as EC, OC, and LC) with the remaining three being moderate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This umbrella review suggested that HE4 was a favored biomarker in the prognosis of cancers, which was supported by high certainty of evidence. Additionally, HE4 could provide a suitable method for the diagnosis of EC, OC, and LC with moderate certainty evidence. Further large prospective cohort studies are needed to better elucidate the diagnostic and prognostic role of HE4 in diseases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.842002","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T01:55:25Z","timestamp":1648518925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["The Role of Human Epididymis Protein 4 in the Diagnosis and Prognosis of Diseases: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies"],"prefix":"10.3389","volume":"9","author":[{"given":"Ming-Li","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Zi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Fan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-Yan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Ting","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molonc.2012.01.010","article-title":"Cancer biomarkers.","volume":"6","author":"Henry","year":"2012","journal-title":"Mol Oncol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000456075","article-title":"Monitoring of serum carcinoembryonic antigen levels after curative resection of colon cancer: cutoff values determined according to preoperative levels enhance the diagnostic accuracy for recurrence.","volume":"92","author":"Saito","year":"2017","journal-title":"Oncology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2010.32.5944","article-title":"Phase I\/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer.","volume":"29","author":"Rudin","year":"2011","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00428-017-2115-1","article-title":"Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.","volume":"470","author":"Stiekema","year":"2017","journal-title":"Virchows Arch."},{"key":"B5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.5603\/GP.2016.0088","article-title":"The role of HE4 and CA125 in differentiation between malignant and non-malignant endometrial pathologies.","volume":"87","author":"Abdalla","year":"2016","journal-title":"Ginekol Pol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1095\/biolreprod45.2.350","article-title":"A major human epididymis-specific cDNA en-codes a protein with sequence homology to extracellular proteinase inhibitors.","volume":"45","author":"Kirchhoff","year":"1991","journal-title":"Biol Reprod."},{"key":"B7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/igc.0000000000000621","article-title":"Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in endometrial cancer: a meta-analysis.","volume":"26","author":"Hu","year":"2016","journal-title":"Int J Gynecol Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cca.2017.05.007","article-title":"HE4 expression in lung cancer, a meta-analysis.","volume":"470","author":"Zhong","year":"2017","journal-title":"Clinica Chimica Acta."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22624","article-title":"Diagnostic performance of CA 125, HE4, and risk of ovarian malignancy algorithm for ovarian cancer.","volume":"33","author":"Kim","year":"2019","journal-title":"J Clin Lab Anal."},{"key":"B10","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.","volume":"63","author":"Hellstr\u00f6m","year":"2003","journal-title":"Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-017-0329-0","article-title":"WAP four-disulfide core domain protein 2 promotes metastasis of human ovarian cancer by regulation of metastasis-associated genes.","volume":"10","author":"Chen","year":"2017","journal-title":"J Ovarian Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.2147\/CMAR.S192950","article-title":"WFDC2 contributes to epithelial-mesenchymal transition (EMT) by activating AKT signaling pathway and regulating MMP-2 expression.","volume":"11","author":"Chen","year":"2019","journal-title":"Cancer Manag Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3890906","article-title":"Human epididymis protein 4 (HE4) reference limits in polish population of healthy women, pregnant women, and women with benign ovarian tumors.","volume":"2019","author":"Gasiorowska","year":"2019","journal-title":"Dis Markers."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017198","article-title":"HE4 as a biomarker for diagnosis of lung cancer: a meta-analysis.","volume":"98","author":"He","year":"2019","journal-title":"Medicine."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007824","article-title":"Potential association between elevated serum human epididymis protein 4 and renal fibrosis: a systemic review and meta-analysis.","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine."},{"key":"B17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3892\/mco.2016.919","article-title":"A new marker for breast cancer diagnosis, human epididymis protein 4: a preliminary study.","volume":"5","author":"G\u00fcnd\u00fcz","year":"2016","journal-title":"Mol Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/IGC.0000000000000913","article-title":"Aberrant MicroRNA expression in patients with endometrial cancer.","volume":"27","author":"Montagnana","year":"2017","journal-title":"Int J Gynecol Cancer."},{"key":"B19","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/aogs.14224","article-title":"The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.","volume":"100","author":"Olsen","year":"2021","journal-title":"Acta Obstet Gynecol Scan."},{"key":"B20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review.","volume":"66","author":"Ferraro","year":"2013","journal-title":"J Clin Pathol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cca.2018.11.011","article-title":"Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: a meta-analysis.","volume":"488","author":"Li","year":"2019","journal-title":"Clin Chim Acta."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-258","article-title":"Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.","volume":"12","author":"Li","year":"2012","journal-title":"BMC Cancer."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-5-20","article-title":"High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer.","volume":"5","author":"Kalapotharakos","year":"2012","journal-title":"J Ovarian Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1007\/s13277-014-1943-8","article-title":"Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer.","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1515\/cclm-2014-0041","article-title":"Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer.","volume":"52","author":"Nagy","year":"2014","journal-title":"Clin Chem Lab Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2147\/OTT.S81853","article-title":"Value of detection of serum human epididymis secretory protein 4 and carbohydrate antigen 125 in diagnosis of early endometrial cancer of dif-ferent pathological subtypes.","volume":"8","author":"Liu","year":"2015","journal-title":"Oncotargets Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews: Methodological development, conduct and reporting of an umbrella review approach.","volume":"13","author":"Aromataris","year":"2015","journal-title":"Int J Evid Based Healthc."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/ijc.31961","article-title":"Risk factors for endometrial cancer: an umbrella review of the literature.","volume":"145","author":"Raglan","year":"2019","journal-title":"Int J Cancer."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1158\/1055-9965.EPI-14-0447","article-title":"HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review.","volume":"23","author":"Karlsen","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025981","article-title":"Diagnostic value of serum human epididymis protein 4 and cancer antigen 125 in the patients with ovarian carcinoma: a protocol for systematic review and meta-analysis.","volume":"100","author":"Dai","year":"2021","journal-title":"Medicine."},{"key":"B32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2020.12.029","article-title":"Endometrial cancer: a systematic review of HE4, REM and REM-B.","volume":"515","author":"Degez","year":"2021","journal-title":"Clinica chimica acta."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med Res Methodol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.ae","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies.","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ."},{"key":"B35","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jclinepi.2014.01.006","article-title":"Applying grading of recommendations assessment, development and evaluation (GRADE) to diagnostic tests was challenging but doable.","volume":"67","author":"Gopalakrishna","year":"2014","journal-title":"J Clin Epidemiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jclinepi.2019.12.023","article-title":"GRADE guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks.","volume":"121","author":"Foroutan","year":"2020","journal-title":"J Clin Epidemiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence.","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epi-demiol."},{"key":"B39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jclinepi.2012.04.012","article-title":"GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence.","volume":"66","author":"Brunetti","year":"2013","journal-title":"J Clin Epi-demiol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/nu11020338","article-title":"DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses.","volume":"11","author":"Chiavaroli","year":"2019","journal-title":"Nutrients."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038450","article-title":"Associations between gastro-oesophageal reflux disease and a range of diseases: an umbrella review of systematic reviews and meta-analyses.","volume":"10","author":"Tan","year":"2020","journal-title":"BMJ Open."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/352670","article-title":"The diagnostic accuracy of HE4 in lung cancer: a meta-analysis.","volume":"2015","author":"Cheng","year":"2015","journal-title":"Dis Markers."},{"key":"B43","first-page":"1974","article-title":"Serum human epididymis protein 4 vs. Carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis.","volume":"20","author":"Chen","year":"2016","journal-title":"Eur Rev Med Pharmaco."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.2147\/CMAR.S178345","article-title":"Prognostic values of HE4 expression in patients with cancer: a meta-analysis.","volume":"10","author":"Dai","year":"2018","journal-title":"Cancer Manag Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.21037\/jtd.2019.06.72","article-title":"Diagnostic accuracy of human epididymis secretory protein 4 for lung cancer: a systematic review and meta-analysis.","volume":"11","author":"Yan","year":"2019","journal-title":"J Thorac Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ejogrb.2020.07.015","article-title":"Meta-analysis of the diagnostic accuracy of HE4 for endometrial carcinoma.","volume":"252","author":"Liu","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"B47","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1515\/cclm-2011-0477","article-title":"Diagnostic value of HE4 for ovarian cancer: a meta-analysis.","volume":"50","author":"Yu","year":"2012","journal-title":"Clin Chem Lab Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2147\/OTT.S45681","article-title":"Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.","volume":"6","author":"Yang","year":"2013","journal-title":"Oncotargets Ther."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-12-169","article-title":"Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis.","volume":"12","author":"Bie","year":"2014","journal-title":"World J Surg Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/IGC.0000000000000192","article-title":"Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis.","volume":"24","author":"Macedo","year":"2014","journal-title":"Int J Gynecol Cancer."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1515\/cclm-2017-1176","article-title":"Prognostic value of HE4 in patients with ovarian cancer.","volume":"56","author":"Yuan","year":"2018","journal-title":"Clin Chem Lab Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"9660","DOI":"10.18632\/oncotarget.14173","article-title":"Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis.","volume":"8","author":"Jia","year":"2017","journal-title":"Oncotarget."},{"key":"B53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejogrb.2018.10.008","article-title":"Diagnostic value of HE4 in ovarian cancer: a meta-analysis.","volume":"231","author":"Huang","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1177\/1533033820971660","article-title":"Role of human epididymis protein 4 (HE4) in determining survival of patients with endometrial cancer: a meta-analysis.","volume":"19","author":"He","year":"2020","journal-title":"Technol Cancer Res T."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015336","article-title":"Diagnostic and prognostic role of HE4 expression in multiple carcinomas: a protocol for systematic review and meta-analysis.","volume":"98","author":"Kumarasamy","year":"2019","journal-title":"Medicine."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-020-00759-9","article-title":"Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer.","volume":"14","author":"Rong","year":"2021","journal-title":"J Ovarian Res."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01697","article-title":"Diagnostic and prognostic values of serum EpCAM, TGM2, and HE4 levels in endometrial cancer.","volume":"10","author":"Lan","year":"2020","journal-title":"Front Oncol."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128836","article-title":"Serum HE4: an independent prognostic factor in non-small cell lung cancer.","volume":"10","author":"Lamy","year":"2015","journal-title":"PLoS One."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s13277-014-2858-0","article-title":"The human epididymis protein 4 acts as a prognostic factor and promotes progression of gastric cancer.","volume":"36","author":"Guo","year":"2015","journal-title":"Tumour biol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0604-6","article-title":"A proposed framework for developing quality assessment tools.","volume":"6","author":"Whiting","year":"2017","journal-title":"System Rev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3892\/mco.2014.279","article-title":"Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: a meta-analysis.","volume":"2","author":"Zhen","year":"2014","journal-title":"Mol clin oncol."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111784","article-title":"Efficacy of HE4, CA125, risk of malignancy index and risk of ovarian malignancy index to detect ovarian cancer in women with presumed benign ovarian tumours: a prospective, multicentre trial.","volume":"8","author":"Dochez","year":"2019","journal-title":"J Clin Med."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-243","article-title":"Human epididymis protein 4 in association with annexin II promotes invasion and metastasis of ovarian cancer cells.","volume":"13","author":"Zhuang","year":"2014","journal-title":"Mol Cancer."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00332","article-title":"Human epididymis protein 4 promotes events associated with metastatic ovarian cancer via regulation of the extracelluar matrix.","volume":"7","author":"Ribeiro","year":"2017","journal-title":"Front Oncol."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037632","article-title":"Diagnosis, treatment and management of apathy in Parkinson\u2019s disease: a scoping review.","volume":"10","author":"Mele","year":"2020","journal-title":"BMJ Open."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/aogs.12235","article-title":"HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).","volume":"92","author":"Antonsen","year":"2013","journal-title":"Acta Obstet Gyn Scan."},{"key":"B67","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.3390\/ijms14036026","article-title":"HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines.","volume":"14","author":"Li","year":"2013","journal-title":"Int J Mol Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1097\/IGC.0b013e3182229ad8","article-title":"Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus.","volume":"21","author":"Moore","year":"2011","journal-title":"Int J Gynecol Cancer."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03225-5","article-title":"Comparison of ELISA with electro-chemiluminescence technology for the qualitative and quantitative assessment of serological responses to vaccination.","volume":"19","author":"Bolton","year":"2020","journal-title":"Malar J."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/bjc.2011.109","article-title":"Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients.","volume":"104","author":"Bignotti","year":"2011","journal-title":"Brit J Cancer."},{"key":"B71","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13277-012-0583-0","article-title":"The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.","volume":"34","author":"Angioli","year":"2013","journal-title":"Tumour Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1007\/s13277-013-0814-z","article-title":"The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.","volume":"34","author":"Omer","year":"2013","journal-title":"Tumour Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3343\/alm.2017.37.6.526","article-title":"Clinical usefulness of human epididymis protein 4 in lung cancer.","volume":"37","author":"Choi","year":"2017","journal-title":"Ann Lab Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3892\/br.2017.971","article-title":"Human epididymis protein 4 may not be a reliable screening biomarker for detecting lung carcinoma patients.","volume":"7","author":"Celik","year":"2017","journal-title":"Biomed Rep."},{"key":"B75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s13277-011-0256-4","article-title":"Human epididymis protein 4 refer-ence limits and natural variation in a Nordic reference population.","volume":"33","author":"Bolstad","year":"2012","journal-title":"Tumour biol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jclinepi.2017.10.012","article-title":"Association between prospective registra-tion and overall reporting and methodological quality of systematic reviews: a meta-epidemiological study.","volume":"93","author":"Ge","year":"2018","journal-title":"J Clin Epidemiol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.842002\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T01:55:31Z","timestamp":1648518931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.842002\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":76,"alternative-id":["10.3389\/fmed.2022.842002"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.842002","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"article-number":"842002"}}